Apimeds Pharmaceuticals US (APUS) Cash & Equivalents (2023 - 2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Cash & Equivalents came in at $1.6 million in Q4 2025, up 47270.62% YoY from N/an in Q4 2024, and down 76.57% on a QoQ basis from $7.0 million in Q3 2025.
Apimeds Pharmaceuticals US (APUS) Cash & Equivalents (2023 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has 3 years of Cash & Equivalents data on file, last reported at $1.6 million in Q4 2025.
- Quarterly Cash & Equivalents rose 47270.62% year-over-year to $1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.6 million (up 47270.62% YoY) and the FY2025 annual result came in at $1.6 million, up 47270.62% from the prior year.
- Cash & Equivalents retreated to $1.6 million in Q4 2025, from $7.0 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $8.7 million in Q2 2025 to a low of $3455.0 in Q4 2024.
- A 3-year average of $3.0 million and a median of $1.0 million in 2023 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2024 — Cash & Equivalents tumbled 99.16% — and 2025, when it surged 47270.62%.
- Tracing APUS's Cash & Equivalents over 3 years: stood at $410481.0 in 2023, then plunged by 99.16% to $3455.0 in 2024, then surged by 47270.62% to $1.6 million in 2025.
- The last three Cash & Equivalents figures came in at $1.6 million (Q4 2025), $7.0 million (Q3 2025), and $8.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 164.00 Mn |
| 10 | Apimeds Pharmaceuticals US | 7.12 Mn | 7.12 Mn | - | 116.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.64 Mn |
| Sep 30, 2025 | 6.99 Mn |
| Jun 30, 2025 | 8.74 Mn |
| Mar 31, 2025 | 250,342.00 |
| Dec 31, 2024 | 3,455.00 |
| Dec 31, 2023 | 410,481.00 |